In 2020, the Chinese orthobiologics market size was valued at $460.7 million, with over 424,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 6% to reach $690.8 million in 2026. Throughout this medical market research, we analyzed 28 orthobiologics companies across China
In 2020, the Indian orthobiologics market size was valued at $76.2 million, with over 520,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 12.4% to reach $172.3 million in 2026. Throughout this medical market research, we analyzed 23 orthobiologics companies across India
In 2020, the Japanese orthobiologics market size was valued at $426.9 million, with over 221,000 bone grafting procedures performed every year. The market size is expected to fluctuate over the forecast period with a -0.4% compound annual growth rate (CAGR). Throughout this medical market research, we analyzed 16 orthobiologics companies across Japan and used our
In 2020, the South Korean orthobiologics market size was valued at $141.6 million, with over 200,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 3.6% to reach $181.5 million in 2026. Throughout this medical market research, we analyzed 16 orthobiologics companies across
In 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026. Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia
The total European orthobiologics market is growing at a rate of 1.6%, which will take the 2018 market value of €521.2 million up to €582.3 million by 2025. Constraints on reimbursements will continue to limit the European orthobiologics market. Presently, only a few premium products under the umbrella of pharmaceuticals are reimbursed by the government
Overall, the U.S. Orthopedic Biomaterials market was valued at $3.7 billion in 2021. This is expected to increase over the forecast period at a CAGR of 3.6% to reach $4.7 billion. Demographic factors in the U.S. continue to be the largest driver within the orthopedic biomaterials market. This is primarily due to the growing elderly
Industry Trends A particular trend in the U.S. orthobiologics market is competitors that are seeking to penetrate high growth segments outside their traditional space by distributing existing products manufactured by other companies, rather than creating their own. This often involves partnering with a company by taking on the costs associated with regulation and market approval,
Bones are biologically active tissues that allow for movement, provide protection for the bodys other organs and serve as a production center for red and white blood cells. When bones are diseased or damaged, bone grafts and bone graft substitutes are used for bridging the resulting void or for providing the support that has been lost. The transplanted (or implanted) material provides a scaffold on which the body can generate new bone tissue, thereby repairing the skeletal system. The most common usage of such materials is for dental implants to replace missing teeth. Within the orthopedic field, however, spinal fusion surgeries are the largest driver of bone graft and bone graft substitute usage. Direct competition for bone graft substitutes comes from bone morphogenetic proteins which, although more expensive, are more effective at stimulating bone growth. Another source of competition is the rise of the motion preservation market for spinal surgery.
Bone is a biologically active tissue and will regenerate whenever possible; however, there are instances where the damage is significant enough to warrant a scaffold to help rejoin the fissure or cavity. Bone grafting is a surgical procedure in which damaged bone is replaced with autograft tissue, allograft tissue or a bone graft substitute, which can be either synthetic or metal.
During an autograft procedure, tissue is harvested from the patients iliac crest, or possibly the distal femur or proximal tibia, and placed at the injury site. An allograft procedure uses donated cadaveric tissue. A grafting procedure using a bone graft substitute replaces human tissue with a synthetic or metal material. For the purposes of this report, metal replacement materials will be excluded, as they are not considered biomaterials.
Cellular allografts consist of allograft bone combined with adipose derived mesenchymal stem cells; or may refer to HCT/P (Human Cells, Tissues, and Cellular and Tissue-based Product) comprised of viable cells within a cortical cancellous bone matrix. The viable cell bone matrix (VCBM) is a cryopreserved cancellous bone combined with demineralized cortical bone matrix. Their key characteristic in regards to bone repair is that they provide osteogenic properties.
Spinal fusion is a surgical procedure designed to combine two or more vertebrae together, eventually forming a fused bone. It is primarily used for eliminating or significantly reducing the pain caused by abnormal movement of the vertebrae by immobilizing them. Supplemental bone tissue, either autograft or allograft, is used for promoting bone growth. A union of two vertebral bodies is referred to as a single-level fusion. Fusion is accomplished by using either an instrumented or non-instrumented surgical approach. Instrumented fusions incorporate fixation devices to secure and stabilize the fusion site, and interbody devices are used for filling the intervertebral disc space to enhance and promote fusion. Non-instrumented fusions utilize bone tissue to promote growth, but do not incorporate any implant devices into the procedures.
Each of the three markets discussed in the report has a unique set of factors affecting its growth profile. In terms of the market drivers, for example, the bone graft market is seeing increasing adoption rate as newly trained surgeons are entering the workforce. The viscosupplementation market continues to bring improved products along with expanded indications. The bone stimulator market maintains a high clinical success rate and is therefore also increasing its adoption rate.
Bone graft substitute products are utilized by dentists/periodontitis, neurosurgeons and orthopedic surgeons. Orthopedic indications represent the most major portion of the bone graft substitute market, with spinal fusions representing the most major category of surgery within that realm. For the purpose of this report, we do not assess the dental bone graft substitute market in any way. Instead, we focus on spinal indications for bone grafts and its size relative to the bone graft substitute market (excluding dental indications).